Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of VERVE-201 in refractory hyperlipidemia
NL-OMON61017Phase 1Recruiting
- Sponsor
- Verve Therapeutics
- Start
- Jul 2026
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, single-arm trial of VERVE-201 in hyperlipidemia, sponsored by Verve Therapeutics. Started Jul 2026; status: recruiting.
02
Drugs
VERVE-201
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NL-OMON61017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61017.